| Not Yet Recruiting | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Colorectal Cancer | Phase 4 | 2026-04-15 |
| Recruiting | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Re Head & Neck Squamous Cell Carcinoma | Phase 2 | 2026-01-27 |
| Recruiting | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic C Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma | Phase 2 | 2025-10-20 |
| Recruiting | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line C Pancreatic Adenocarcinoma Advanced or Metastatic | Phase 3 | 2025-03-27 |
| Recruiting | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treat Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 2 | 2025-02-20 |
| Recruiting | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastati Colorectal Cancer | Phase 3 | 2024-11-15 |
| Active Not Recruiting | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Colorectal Cancer | Phase 2 | 2024-07-23 |
| Terminated | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients Colorectal Cancer Metastatic | Phase 2 | 2024-03-13 |
| Recruiting | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Gastric Cancer, HER2-positive Gastric Cancer | Phase 2 | 2024-03-01 |
| Recruiting | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | 2023-11-07 |
| Suspended | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer | Phase 2 | 2023-05-17 |
| Recruiting | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Colorectal Cancer, Resectable Colorectal Carcinoma | Phase 2 | 2023-05-11 |
| Active Not Recruiting | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery Merkel Cell Carcinoma | Phase 2 | 2022-12-07 |
| Recruiting | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer Nasopharyngeal Carcinoma | Phase 2 | 2022-03-24 |
| Active Not Recruiting | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patien Colorectal Cancer Metastatic | Phase 1 / Phase 2 | 2022-01-25 |
| Active Not Recruiting | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 Locally Advanced Rectal Cancer | Phase 2 | 2022-01-25 |
| Active Not Recruiting | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. Gastric Cancer, Microsatellite Instability | Phase 2 | 2021-04-01 |
| Recruiting | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-02-08 |
| Unknown | Tailored Sonidegib Schedule After Complete Response in BCC Locally Advanced Basal Cell Carcinoma | Phase 2 | 2021-01-12 |
| Active Not Recruiting | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence Colorectal Cancer | Phase 2 | 2020-12-15 |
| Completed | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patient Metastatic Colorectal Cancer | Phase 2 | 2020-04-01 |
| Unknown | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Nasopharyngeal Carcinoma, EBV Related Carcinoma | Phase 2 | 2019-06-30 |
| Completed | Immunotherapy In Locally Advanced Rectal Cancer Colon Rectal Cancer | Phase 2 | 2019-04-01 |
| Unknown | Targeting the Tumor Microenvironment in R/M SCCHN Head and Neck Cancer | Phase 1 / Phase 2 | 2019-01-07 |
| Completed | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cance Metastatic Colorectal Cancer | Phase 2 | 2018-11-30 |
| Unknown | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Car Squamous Cell Anal Carcinoma | Phase 2 | 2018-09-18 |
| Completed | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN Squamous Cell Carcinoma of Head and Neck | Phase 3 | 2017-11-27 |
| Completed | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER P Metastatic Colorectal Cancer | Phase 3 | 2017-09-13 |
| Unknown | Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elde Elderly Metastatic Colorectal Cancer Patients | Phase 2 | 2016-07-01 |
| Unknown | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Foll Metastatic Colorectal Cancer | Phase 3 | 2015-02-26 |
| Unknown | Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With An Metastatic Colorectal Cancer | Phase 2 | 2014-10-01 |
| Completed | Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient Metastatic Colorectal Cancer | Phase 2 | 2011-10-01 |
| Completed | FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer Metastatic Colo-rectal Cancer | Phase 2 | 2010-03-01 |
| Unknown | Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Squamous Cell Carcinoma of the Head and Neck | Phase 3 | 2009-09-01 |
| Completed | Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Colorectal Cancer | Phase 3 | 2008-07-01 |
| Terminated | Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorect Colorectal Cancer | Phase 3 | 2008-06-01 |
| Completed | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer Colorectal Cancer Metastatic | Phase 2 | 2007-07-01 |
| Completed | FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 3 | 2001-11-01 |